X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (XFOR) has announced the issuance of inducement awards to new employees under its 2019 Inducement Plan. The awards, effective January 31, 2025, consist of options to purchase 450,471 shares of X4's common stock at an exercise price of $0.2030 per share, matching the closing price on April 22, 2025.
The stock options, granted in accordance with Nasdaq Listing Rule 5635(c)(4), feature a ten-year term and a four-year vesting schedule. The vesting structure includes 25% of shares vesting after 12 months, followed by monthly vesting of the remaining shares over 36 months, contingent on continued employment.
X4 Pharmaceuticals (XFOR) ha annunciato l'assegnazione di premi di incentivazione a nuovi dipendenti nell'ambito del suo Piano di Incentivazione 2019. I premi, con efficacia dal 31 gennaio 2025, consistono in opzioni per l'acquisto di 450.471 azioni ordinarie di X4 al prezzo di esercizio di 0,2030 $ per azione, corrispondente al prezzo di chiusura del 22 aprile 2025.
Le opzioni azionarie, concesse in conformità con la Regola Nasdaq 5635(c)(4), hanno una durata di dieci anni e un piano di maturazione quadriennale. La struttura prevede il maturare del 25% delle azioni dopo 12 mesi, seguito da un maturare mensile delle restanti azioni nei successivi 36 mesi, subordinato alla permanenza in servizio.
X4 Pharmaceuticals (XFOR) ha anunciado la emisión de premios de incentivo para nuevos empleados bajo su Plan de Incentivos 2019. Los premios, efectivos a partir del 31 de enero de 2025, consisten en opciones para comprar 450,471 acciones ordinarias de X4 a un precio de ejercicio de $0.2030 por acción, igualando el precio de cierre del 22 de abril de 2025.
Las opciones sobre acciones, otorgadas conforme a la Regla Nasdaq 5635(c)(4), tienen un plazo de diez años y un calendario de adquisición de derechos de cuatro años. La estructura de adquisición incluye el 25% de las acciones después de 12 meses, seguido por la adquisición mensual de las acciones restantes durante los siguientes 36 meses, condicionado a la continuidad en el empleo.
X4 Pharmaceuticals (XFOR)는 2019년 유인 계획에 따라 신입 직원에게 유인 보상을 발행한다고 발표했습니다. 이 보상은 2025년 1월 31일부터 효력이 발생하며, 2025년 4월 22일 종가와 동일한 주당 $0.2030의 행사 가격으로 450,471주의 보통주를 매수할 수 있는 옵션으로 구성됩니다.
이 주식 옵션은 나스닥 상장 규칙 5635(c)(4)에 따라 부여되었으며, 10년의 유효 기간과 4년의 권리 취득 일정이 포함되어 있습니다. 권리 취득 구조는 12개월 후 25%의 주식이 취득되고, 이후 36개월 동안 매월 나머지 주식이 취득되며, 계속 근무 조건이 충족되어야 합니다.
X4 Pharmaceuticals (XFOR) a annoncé l'attribution de primes d'incitation à de nouveaux employés dans le cadre de son Plan d'Incitation 2019. Ces primes, effectives à partir du 31 janvier 2025, consistent en des options d'achat de 450 471 actions ordinaires de X4 au prix d'exercice de 0,2030 $ par action, correspondant au cours de clôture du 22 avril 2025.
Les options d'achat d'actions, accordées conformément à la règle Nasdaq 5635(c)(4), ont une durée de dix ans et un calendrier d'acquisition des droits sur quatre ans. La structure prévoit l'acquisition de 25 % des actions après 12 mois, suivie d'une acquisition mensuelle des actions restantes sur 36 mois, sous réserve de la poursuite de l'emploi.
X4 Pharmaceuticals (XFOR) hat die Ausgabe von Anreizprämien an neue Mitarbeiter im Rahmen seines Inducement-Plans von 2019 bekanntgegeben. Die Prämien, wirksam ab dem 31. Januar 2025, bestehen aus Optionen zum Kauf von 450.471 Aktien der Stammaktien von X4 zu einem Ausübungspreis von 0,2030 $ pro Aktie, entsprechend dem Schlusskurs am 22. April 2025.
Die Aktienoptionen, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt wurden, haben eine Laufzeit von zehn Jahren und einen vierjährigen Vesting-Zeitplan. Die Vesting-Struktur sieht vor, dass 25 % der Aktien nach 12 Monaten vesten, gefolgt von einer monatlichen Vesting der restlichen Aktien über 36 Monate, vorausgesetzt, die Beschäftigung wird fortgesetzt.
- None.
- None.
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 450,471 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
What are the key terms of XFOR's 2025 inducement stock options grant?
How long is the vesting period for XFOR's new employee stock options?
What is the exercise price of XFOR's April 2025 inducement stock options?
When do XFOR's 2025 inducement stock options expire?
